Abstract
Objectives During March 2020, the COVID-19 pandemic has rapidly spread globally, and non-pharmaceutical interventions are being used to reduce both the load on the healthcare system as well as overall mortality.
Design Individual-based transmission modelling using Swedish demographic and Geographical Information System data and conservative COVID-19 epidemiological parameters.
Setting Sweden
Participants A model to simulate all 10.09 million Swedish residents.
Interventions 5 different non-pharmaceutical public-health interventions including the mitigation strategy of the Swedish government as of 10 April; isolation of the entire household of confirmed cases; closure of schools and non-essential businesses with or without strict social distancing; and strict social distancing with closure of schools and non-essential businesses.
Main outcome measures Estimated acute care and intensive care hospitalisations, COVID-19 attributable deaths, and infections among healthcare workers from 10 April until 29 June.
Findings Our model for Sweden shows that, under conservative epidemiological parameter estimates, the current Swedish public-health strategy will result in a peak intensive-care load in May that exceeds pre-pandemic capacity by over 40-fold, with a median mortality of 96,000 (95% CI 52,000 to 183,000). The most stringent public-health measures examined are predicted to reduce mortality by approximately three-fold. Intensive-care load at the peak could be reduced by over two-fold with a shorter period at peak pandemic capacity.
Conclusions Our results predict that, under conservative epidemiological parameter estimates, current measures in Sweden will result in at least 40-fold over-subscription of pre-pandemic Swedish intensive care capacity, with 15.8 percent of Swedish healthcare workers unable to work at the pandemic peak. Modifications to ICU admission criteria from international norms would further increase mortality.
What is already known?
- The COVID-19 pandemic has spread rapidly in Europe and globally since March 2020.
- Mitigation and suppression methods have been suggested to slow down or halt the spread of the COVID-19 pandemic. Most European countries have enacted strict suppression measures including lockdown, school closures, enforced social distancing; while Sweden has chosen a different strategy of milder mitigation as of today (10 April 2020).
- Different national policy decisions have been justified by socio-geographic differences among countries. Such differences as well as the tempo and stringency of public-health interventions are likely to affect the impact on each country’s mortality and healthcare system.
What this study adds?
- Individual-based modelling of COVID-19 spread using Swedish demographics and conservative epidemiological assumptions indicates that the peak of the number of hospitalised patients with COVID-19 can be expected in early May under the current strategy, shifted earlier and attenuated with more stringent public health measures.
- Healthcare needs are expected to substantially exceed pre-pandemic capacity even if the most aggressive interventions considered were implemented in the coming weeks. In particular the need for intensive care unit beds will be at least 40-fold greater than the pre-pandemic capacity if the current strategy is maintained, and at least 10-fold greater if strategies approximating the most stringent in Europe are introduced by 10 April.
- Our model predicts that, using median infection-fatality-rate estimates, at least 96,000 deaths would occur by 1 July without mitigation. Current policies reduce this number by approximately 15%, while even more aggressive social distancing measures, such as adding household isolation or mandated social distancing can reduce this number by more than 50%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
LW received funding from the Research Foundation Flanders (1234620N) and from the Epipose project from the European Union’s SC1-PHE- CORONAVIRUS-2020 programme (101003688). SCLK and PK received funding from the Knut and Alice Wallenberg Foundation (2018.0140 and 2019.0431). The simulations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC 2020/5-176) at HPC2N in Umeå, UPPMAX in Uppsala, NSC in Linköping, and PDC in Stockholm, partially funded by the Swedish Research Council through grant agreement no. 2016-07213. The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Copyright/license for publication The Corresponding Authors have the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work (relevant funding is mentioned in the acknowledgements); no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Contributor and guarantor information
Substantial contributions to the conception or design of the work (JMG, LW, WVDW, SCLK, NB, PK); or the acquisition, analysis (JMG), or interpretation of data (JMG, WVDW, LW, SCLK, NB, PK) for the work; AND
Drafting the work or revising it critically for important intellectual content (JMG, LW, WVDW, SCLK, NB, PK); AND
Final approval of the version to be published (JMG, LW, WVDW, SCLK, NB, PK); AND
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (JMG, LW, WVDW, SCLK, NB, PK).
The corresponding authors (SCLK, NB, PK) attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.
Transparency declaration: SCLK, NB and PK, the guarantors of the manuscript, affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained. They accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.
Data Availability
The code implementing this model and the interventions tested will be made freely available on https://github.com/kassonlab/covid19-epi. Results files are available on Zenodo (DOI:10.5281/zenodo.3748120).
